Clinical Trial Detail

NCT ID NCT03302234
Title Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-small Cell Lung Cancer (MK-3475-598/KEYNOTE-598)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Merck Sharp & Dohme Corp.

lung non-small cell carcinoma



Ipilimumab + Pembrolizumab

Age Groups: adult senior

Additional content available in CKB BOOST